GLP-1 is contraindicated in patients including but not limited to: those with a personal or family history of medullary thyroid cancer, patients with multiple endocrine neoplasia type 2, patients with a hypersensitivity reaction to GLP-1 or any of the product components, as well as patients with pancreatitis, kidney disease, diabetic retinopathy or gallbladder disease
Use trained personnel, appropriate engineering controls, personal protective equipment, contamination controls, and lawful disposal methods
The Phase 2 NEJM trial showed 24.2% average body weight reduction at 48 weeks in the 12mg group
This phenomenon, marked by celebrity endorsements, media attention, online sales, and widespread social media discussion, reflects more than a medical trend